Your browser doesn't support javascript.
loading
Remdesivir for Treatment of COVID-19 Requiring Oxygen Support: A Cross-Study Comparison from Two Large, Open-Label Studies.
Fusco, Dahlene; Malenica, Ivana; Günthard, Huldrych F; Gupta, Samir K; Kurbegov, Dax; Balani, Bindu; Olender, Susan; Aberg, Judith A; Telep, Laura E; Tian, Yuan; Blair, Christiana; Wu, George; Haubrich, Richard; Wang, Chen-Yu; Chokkalingam, Anand P; Osinusi, Anu O; Wendtner, Clemens-Martin; Gottlieb, Robert L.
Afiliação
  • Fusco D; Tulane Medical Center, New Orleans, Louisiana, USA.
  • Malenica I; Gilead Sciences, Inc., Foster City, California, USA.
  • Günthard HF; University of California, Berkeley, Berkeley, California, USA.
  • Gupta SK; University Hospital Zurich, Zurich, Switzerland.
  • Kurbegov D; Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Balani B; Sarah Cannon, Nashville, Tennessee, USA.
  • Olender S; Hackensack School of Medicine, Hackensack University Medical Center, Hackensack, New Jersey, USA.
  • Aberg JA; Columbia University in the City of New York, New York, USA.
  • Telep LE; Icahn School of Medicine at Mount Sinai, New York, USA.
  • Tian Y; Gilead Sciences, Inc., Foster City, California, USA.
  • Blair C; Gilead Sciences, Inc., Foster City, California, USA.
  • Wu G; Gilead Sciences, Inc., Foster City, California, USA.
  • Haubrich R; Gilead Sciences, Inc., Foster City, California, USA.
  • Wang CY; Gilead Sciences, Inc., Foster City, California, USA.
  • Chokkalingam AP; Gilead Sciences, Inc., Foster City, California, USA.
  • Osinusi AO; Gilead Sciences, Inc., Foster City, California, USA.
  • Wendtner CM; Gilead Sciences, Inc., Foster City, California, USA.
  • Gottlieb RL; Munich Clinic Schwabing, Academic Teaching Hospital, Ludwig-Maximilians-University, Munich, Germany.
Clin Infect Dis ; 2024 Jun 26.
Article em En | MEDLINE | ID: mdl-38920297
ABSTRACT

BACKGROUND:

Remdesivir, an RNA-polymerase prodrug inhibitor approved for treatment of COVID-19, shortens recovery time and improves clinical outcomes. This prespecified analysis compared remdesivir plus standard-of-care (SOC) with SOC alone in adults hospitalized with COVID-19 requiring oxygen support in the early stage of the pandemic.

METHODS:

Data for 10-day remdesivir treatment plus SOC from the extension phase of an open-label study (NCT04292899) were compared with real-world, retrospective data on SOC alone (EUPAS34303). Both studies included patients aged ≥18 years hospitalized with SARS-CoV-2 up to 30 May 2020, with oxygen saturation ≤94%, on room air or supplemental oxygen (all forms), and with pulmonary infiltrates. Propensity score weighting was used to balance patient demographics and clinical characteristics across treatment groups. The primary endpoint was time to all-cause mortality or end of study (day 28). Time-to-discharge, with a 10-day landmark to account for duration of remdesivir treatment, was a secondary endpoint.

RESULTS:

1974 patients treated with remdesivir plus SOC, and 1426 with SOC alone, were included after weighting. Remdesivir significantly reduced mortality versus SOC (hazard ratio [HR] 0.46, 95% confidence interval 0.39-0.54). This association was observed at each oxygen support level, with the lowest HR for patients on low-flow oxygen. Remdesivir significantly increased the likelihood of discharge at day 28 versus SOC in the 10-day landmark analysis (HR 1.64; 95% confidence interval 1.43-1.87).

CONCLUSIONS:

Remdesivir plus early-2020 SOC was associated with a 54% lower mortality risk and shorter hospital stays compared with SOC alone in patients hospitalized with COVID-19 requiring oxygen support. CLINICAL TRIALS REGISTRATION ClinicalTrials.gov NCT04292899 and EUPAS34303.
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Clin Infect Dis Assunto da revista: DOENCAS TRANSMISSIVEIS Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Clin Infect Dis Assunto da revista: DOENCAS TRANSMISSIVEIS Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Estados Unidos